The research progress of understanding the etiology and pathogenesis of Parkinson's
disease (PD) has yet lead to the development of some clinical approaches intended to treat …

Background: The majority of current pharmacological treatments for Parkinson's disease
(PD) were approved for clinical use in the second half of the last century and they only …

Parkinson's disease (PD) is the second-leading cause of dementia and is characterized by a
progressive loss of dopaminergic neurons in the substantia nigra alongside the presence of …

Parkinson's disease (PD) usually presents in older adults and typically has both motor and
non-motor dysfunctions. PD is a progressive neurodegenerative disorder resulting from …

Since the 1960's treatments for Parkinson's disease (PD) have traditionally been directed to
restore or replace dopamine, with L-Dopa being the gold standard. However, chronic L …

This article summarizes (1) the recent achievements to further improve symptomatic therapy
of motor Parkinson's disease (PD) symptoms,(2) the still-few attempts to systematically …

Parkinson disease (PD) is an age-related neurodegenerative disorder that affects as many
as 1–2% of persons aged 60 years and older. With the aging of the population, the …

Updates and advances in the treatment of Parkinson disease | The Medical Journal of
Australia MJA Basic Search Advanced search search Use the Advanced search for more …

Treatments with potential neuroprotective capability for Parkinson's disease (PD) have been
investigated in randomized, controlled, clinical trials and other studies since the mid-1980s …

Traditionally, the basal ganglia have been considered the main brain region implicated in
Parkinson's disease. This single area perspective gives a restricted clinical picture and limits …